IFP Advisors Inc Purchases 442 Shares of Edwards Lifesciences Corporation $EW

IFP Advisors Inc lifted its position in Edwards Lifesciences Corporation (NYSE:EW) by 7.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 6,545 shares of the medical research company’s stock after purchasing an additional 442 shares during the period. IFP Advisors Inc’s holdings in Edwards Lifesciences were worth $512,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Jennison Associates LLC grew its holdings in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Edwards Lifesciences by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock worth $491,673,000 after purchasing an additional 264,311 shares during the last quarter. Nuveen LLC bought a new position in shares of Edwards Lifesciences in the first quarter worth approximately $330,881,000. Invesco Ltd. lifted its stake in Edwards Lifesciences by 2.6% in the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after acquiring an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Edwards Lifesciences by 5.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after acquiring an additional 198,882 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $73.39 on Wednesday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $43.09 billion, a P/E ratio of 10.56, a P/E/G ratio of 3.50 and a beta of 1.05. The business has a fifty day simple moving average of $77.83 and a two-hundred day simple moving average of $76.16. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. Mizuho raised their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Evercore ISI set a $88.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft raised their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.06.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.